48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse

Table 1

Baseline characteristics of 62 patients before NA treatment cessation.

	origin HBeAg positive; ()	origin HBeAg negative; ()	All; ()
Age, year	33.18 ± 8.33	44.39 ± 8.99	37.34 ± 10.11
Gender, male (%)	26 (66.7)	19 (82.6)	45 (72.6)
BMI, kg/cm^2	21.31 ± 2.91	23.01 ± 3.12	21.95 ± 3.08
NA treatment, ratio of ETV : LDT : LAM : ADV : LAM +	10 : 17 : 3 : 5 : 4	9 : 6 : 2 : 2 : 4	19 : 23 : 5 : 7 : 8
Duration of NA treatment, year	4.64 ± 2.63	4.33 ± 1.74	4.52 ± 2.33
Duration of negative HBV DNA maintenance, year	3.83 ± 2.15	3.68 ± 1.31	3.78 ± 1.87
Duration of HBeAg seroconversion maintenance, year	3.19 ± 2.47	-	-
EOT HBsAg, (IU/mL	2.65 ± 1.22	2.36 ± 1.38	2.54 ± 1.28

: nucleos(t)ide analogues; ETV: entecavir; LDT: telbivudine; LAM: lamivudine; ADV: adefovir dipivoxil; : end of treatment.